What is Apraglutide?
Apraglutide (development code FE 203799) is a synthetic long-acting analogue of glucagon-like peptide-2 (GLP-2) designed for once-weekly subcutaneous administration. It is developed by Ironwood Pharmaceuticals (originally VectivBio, acquired by Ironwood in 2023) for short bowel syndrome with intestinal failure (SBS-IF) — the same indication as teduglutide (Gattex), with the major advantage of weekly rather than daily dosing.
Apraglutide met its Phase 3 primary endpoint in 2024 and Ironwood has stated NDA submission is planned, positioning apraglutide for potential FDA approval in the late 2026 / early 2027 timeframe.
Background — GLP-2 and SBS-IF
GLP-2 is an endogenous 33-amino-acid peptide co-secreted with GLP-1 from intestinal L-cells. Its physiologic role is to promote intestinal mucosal growth, slow transit, reduce permeability, and increase splanchnic blood flow.
In SBS-IF, surgical resection of the small intestine reduces absorptive surface below the threshold for autonomous nutrition. Patients require chronic parenteral support (PS) — partial or complete IV nutrition and fluid administration. Pharmacologic stimulation of mucosal growth in the residual intestine can reduce PS requirements and improve quality of life.
Teduglutide (FDA 2012) was the first approved GLP-2 analogue for this indication. Its limitation: daily subcutaneous injection.
Mechanism of Action
Apraglutide acts on the GLP-2 receptor identically to native GLP-2 and teduglutide:
- Promotes intestinal crypt cell proliferation and villus growth
- Increases mucosal absorptive surface
- Slows gastric emptying
- Reduces intestinal permeability
The pharmacological innovation is in the half-life extension:
- Apraglutide is engineered with multiple modifications conferring DPP-4 resistance and extended plasma residency
- The result is a half-life supporting once-weekly subcutaneous dosing
- Native GLP-2 has a ~7-minute half-life; teduglutide ~2 hours; apraglutide ~30+ hours
Clinical Evidence
STARS Phase 3 (NCT04964986, 2024):
- 164 patients with SBS-IF on stable parenteral support, randomized to once-weekly apraglutide vs placebo for 24 weeks
- Primary endpoint — relative change in weekly PS volume:
- Apraglutide: −25.5%
- Placebo: −12.5%
- Treatment difference statistically significant (p=0.001)
- Consistent treatment effect across baseline demographics, etiologies, and PS volume strata
Long-term extension and pediatric Phase 3 ongoing.
Pipeline Status
- Phase 3 STARS positive (2024)
- NDA submission planned by Ironwood
- Pediatric Phase 3 ongoing
- Approval timing uncertain pending FDA review of NDA
Place in Future Therapy
If approved, apraglutide would compete directly with teduglutide:
| Feature | Teduglutide (Gattex) | Apraglutide |
|---|---|---|
| Class | GLP-2 analogue | GLP-2 analogue |
| Dosing | Once daily SC | Once weekly SC |
| Approval | FDA 2012 (adult), 2019 (peds) | Phase 3, NDA pending |
| Half-life | ~2 hours | ~30+ hours |
The dosing convenience advantage is substantial for chronic outpatient SBS-IF management — particularly for patients managing parenteral nutrition at home.
Distinction from Glepaglutide
Glepaglutide is another long-acting GLP-2 analogue developed by Zealand Pharma, dosed twice weekly. Its Phase 3 EASE-1 trial was positive but the FDA issued a Complete Response Letter in December 2024 requesting additional clinical data. Apraglutide and glepaglutide represent the two leading next-generation GLP-2 candidates; apraglutide is currently further ahead in the FDA review process.
Safety Profile
Phase 3 adverse events were similar to teduglutide:
- Abdominal pain, nausea, abdominal distension (reflective of intestinal pharmacology)
- Injection-site reactions
- Fluid overload risk during PS reduction
GLP-2 class concerns (cholelithiasis, theoretical neoplastic growth promotion in pre-existing GI tumors) apply to apraglutide as a class effect. Pre-treatment colonoscopy and ongoing monitoring are expected to be standard.